Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m)

• David Q. Beversdorf,
• Evdokia Anagnostou,
• Antonio Hardan,
• Paul Wang,
• Craig A. Erickson,
• Craig A. Erickson,
• Thomas W. Frazier,
• Thomas W. Frazier,
• Jeremy Veenstra-VanderWeele,
• Jeremy Veenstra-VanderWeele

Affiliations

David Q. Beversdorf

Departments of Radiology, Neurology, and Psychological Sciences, William and Nancy Thompson Endowed Chair in Radiology, University of Missouri, Columbia, MO, United States

Evdokia Anagnostou

Holland Bloorview Kids Rehabilitation Hospital, University of Toronto, Toronto, ON, Canada

Antonio Hardan

Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States

Paul Wang

Clinical Research Associates LLC, Simons Foundation, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, United States

Craig A. Erickson

Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States

Craig A. Erickson

Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States

Thomas W. Frazier

Department of Psychology, John Carroll University, University Heights, OH, United States

Thomas W. Frazier

Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, NY, United States

Jeremy Veenstra-VanderWeele

Departments of Psychiatry and Pediatrics, New York State Psychiatric Institute, Columbia University, New York, NY, United States

Jeremy Veenstra-VanderWeele

0NewYork-Presbyterian Center for Autism and the Developing Brain, New York, NY, United States